Narges K Gortany1,2, Ghodratollah Panahi3, Homanaz Ghafari2, Maryam Shekari2, Mahmoud Ghazi-Khansari4,5. 1. Cancer Biology Research Center, Cancer Institute of I.R. Iran, Tehran University of Medical Sciences, Tehran, Iran. 2. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran. 3. Department of Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 4. Cancer Biology Research Center, Cancer Institute of I.R. Iran, Tehran University of Medical Sciences, Tehran, Iran. ghazikha@tums.ac.ir. 5. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran. ghazikha@tums.ac.ir.
Abstract
PURPOSE: Glioblastoma multiforme (GBM) is one of the most aggressive human cancers. The c-MET receptor tyrosine kinase (RTK) which is frequently deregulated in GBM is considered as a promising target for GBM treatment. The c-MET plays a key role in cell proliferation, cell cycle progression, invasion, angiogenesis, and metastasis. Here, we investigated the anti-tumour activity of foretinib, a c-MET inhibitor, on three human GBM cells (T98G, U87MG and U251). METHODS: Anti-proliferative effect of foretinib was determined using MTT, crystal violet staining, and clonogenic assays. PI and Annexin V/PI staining flow cytometry were used to evaluate the effects of foretinib on cell cycle and apoptosis, respectively. Scratch assay, qRT-PCR, western blot, and zymography analyses were applied to elucidate the molecular mechanisms underlying the anti-tumour activity of foretinib. RESULTS: Foretinib treatment reduced phosphorylation of c-MET on T98G and U251 cells, but not in U87MG cells. The highest inhibitory effect was observed in T98G cells (IC50 = 4.66 ± 0.29 µM) and the lowest one in U87MG cells (IC50 = 29.99 ± 1.31 µM). The results showed that foretinib inhibited the proliferation of GBM cells through a G2/M cell cycle arrest and mitochondrial-mediated apoptosis in association with alternation in expression of the related genes and protein-regulated G2/M phase and apoptosis. Foretinib diminished GBM cell invasion through downregulation of the proteolytic cascade of MMP2, uPA and uPAR and epithelial-mesenchymal transition (EMT)-related genes. A different GBM cell sensitivity pattern was noticeable in all experiments which demonstrated T98G as a sensitive and U87MG as a resistant phenotype to foretinib treatment. CONCLUSION: The results indicated that foretinib might have the therapeutic potential against human GBM which deserve further investigation.
PURPOSE:Glioblastoma multiforme (GBM) is one of the most aggressive humancancers. The c-METreceptor tyrosine kinase (RTK) which is frequently deregulated in GBM is considered as a promising target for GBM treatment. The c-MET plays a key role in cell proliferation, cell cycle progression, invasion, angiogenesis, and metastasis. Here, we investigated the anti-tumour activity of foretinib, a c-MET inhibitor, on three human GBM cells (T98G, U87MG and U251). METHODS: Anti-proliferative effect of foretinib was determined using MTT, crystal violet staining, and clonogenic assays. PI and Annexin V/PI staining flow cytometry were used to evaluate the effects of foretinib on cell cycle and apoptosis, respectively. Scratch assay, qRT-PCR, western blot, and zymography analyses were applied to elucidate the molecular mechanisms underlying the anti-tumour activity of foretinib. RESULTS:Foretinib treatment reduced phosphorylation of c-MET on T98G and U251 cells, but not in U87MG cells. The highest inhibitory effect was observed in T98G cells (IC50 = 4.66 ± 0.29 µM) and the lowest one in U87MG cells (IC50 = 29.99 ± 1.31 µM). The results showed that foretinib inhibited the proliferation of GBM cells through a G2/M cell cycle arrest and mitochondrial-mediated apoptosis in association with alternation in expression of the related genes and protein-regulated G2/M phase and apoptosis. Foretinib diminished GBM cell invasion through downregulation of the proteolytic cascade of MMP2, uPA and uPAR and epithelial-mesenchymal transition (EMT)-related genes. A different GBM cell sensitivity pattern was noticeable in all experiments which demonstrated T98G as a sensitive and U87MG as a resistant phenotype to foretinib treatment. CONCLUSION: The results indicated that foretinib might have the therapeutic potential against human GBM which deserve further investigation.
Authors: K Nabeshima; Y Shimao; S Sato; H Kataoka; T Moriyama; H Kawano; S Wakisaka; M Koono Journal: Histopathology Date: 1997-11 Impact factor: 5.087
Authors: Gautam Maulik; Takashi Kijima; Patrick C Ma; Sudip K Ghosh; Jeffrey Lin; Geoffrey I Shapiro; Erik Schaefer; Elena Tibaldi; Bruce E Johnson; Ravi Salgia Journal: Clin Cancer Res Date: 2002-02 Impact factor: 12.531
Authors: Fawn Qian; Stefan Engst; Kyoko Yamaguchi; Peiwen Yu; Kwang-Ai Won; Lillian Mock; Tracy Lou; Jenny Tan; Connie Li; Danny Tam; Julie Lougheed; F Michael Yakes; Frauke Bentzien; Wei Xu; Tal Zaks; Richard Wooster; Joel Greshock; Alison H Joly Journal: Cancer Res Date: 2009-10-06 Impact factor: 12.701
Authors: Manish A Shah; Zev A Wainberg; Daniel V T Catenacci; Howard S Hochster; James Ford; Pamela Kunz; Fa-Chyi Lee; Howard Kallender; Fabiola Cecchi; Daniel C Rabe; Harold Keer; Anne-Marie Martin; Yuan Liu; Robert Gagnon; Peter Bonate; Li Liu; Tona Gilmer; Donald P Bottaro Journal: PLoS One Date: 2013-03-14 Impact factor: 3.752
Authors: Nikolay Konovalov; Stanislav Timonin; Dmitry Asyutin; Mikhail Raevskiy; Maxim Sorokin; Anton Buzdin; Stanislav Kaprovoy Journal: Front Oncol Date: 2022-03-21 Impact factor: 6.244